The global gout therapeutic market is driven by high prevalence and rapid increase in incidence of gout arthritis across the globe. The global gout therapeutics market was valued at US$ 1874 Mn in 2018 and is projected to reach US$ 3820 Mn by 2027, expanding at a CAGR of 8.3% from 2019 to 2027.

High growth rate of the gout therapeutics market is attributed because of following factors

  • Increase in drug pipeline
  • Easy availability,
  • Rise in the demand for biologics for treatment of gout across the globe. 

Gout is a type of inflammatory arthritis caused by small crystals of a chemical called uric acid that form in the joints. If uric acid levels in the blood remain elevated, thin rod-like crystals can form and deposit in the joints, which can lead to severe pain, tenderness, stiffness, swelling, and joint damage. 

Gout has both active and inactive periods. Active periods of gout are known as ‘attacks’ and can vary in severity and length. Diagnosis of gout is confirmed by synovial fluid analysis. Incidence of gout has been rising consistently over the last few years.

  • According to Nationwide Emergency Department Sample (NEDS), total number of ED visits per year among patients with a primary diagnosis of acute gout increased 26.8% between 2006 and 2014; from 168,580 to 213,780. 

Traditional therapies are witnessing a shift toward biologics. Rise in demand for effective treatment and new therapeutics launches are projected to propel the global gout therapeutics market during the forecast period. Efforts are being taken in various countries to spread awareness about chronic diseases and role of biologics in treating gout among the general population. 

The global gout therapeutic market has been segmented based on drug type, distribution channel, and region. In terms of drug type, the gout therapeutics market has been classified into NSAIDS, colchicine, corticosteroids, antihyperuricemic agents (urate-lowering drugs), and biologics. The antihyperuricemic agents (urate-lowering drugs) segment dominated the gout therapeutics market in 2018. 

The segment is projected to expand at a high CAGR from 2019 to 2027. Biologics have witnessed rapid adoption and are replacing NSAIDS and corticosteroids owing to better results. Hence, the biologics segment is anticipated to expand at a rapid pace and is likely to gain gout therapeutics market share during the forecast period. 

Antihyperuricemic agents (urate-lowering drugs) are usually prescribed as the first line of treatment. Moreover, adoption and success of Target-2-Treat (T2T) strategy using a combination of biologic and conventional synthetic urate-lowering drugs for the treatment of severe gout disease are key factors fueling biologic and antihyperuricemic agents segments. 

Based on distribution channel, the global gout therapeutics market has been categorized into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment accounted for major share of the global market in 2018, followed by hospital pharmacy and online pharmacy segments. 

global gout therapeutics market 2

Increase in the number of multinational hospitals and preference to take injectable biologic drug products at hospitals is estimated to drive the hospital pharmacy segment.

  • Increasing number of hospitals in developing countries, such as India China, Singapore, and Malaysia is further fueling the segment. 

In terms of region, the global gout therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for significant share of the global market in 2018, followed by Europe.

global gout therapeutics market

Well-established health care facilities, favorable reimbursement policies, and early adoption of therapeutics for the treatment of gout contributed to the high gout therapeutics market share held by North America. Europe is projected to be the second-most attractive market for gout therapeutics from 2019 to 2027.

The gout therapeutics market in the Europe is anticipated to expand at a high CAGR during the forecast period, due to high prevalence and increase in incidence of gout and high per capita health care expenditure in the region. 

The global gout therapeutics market is consolidated, with several companies accounting for majority market share. Key players operating in the global market include Takeda Pharmaceutical Company Limited, Teijin Pharma Limited., Novartis AG, Mylan N.V., and Horizon Pharma plc. These players exhibit significant geographic outreach, with presence in multiple gout therapeutics segments. 

Manufacturers are adopting acquisition & collaboration and new product development strategies to tap the unmet needs of a large proportion of patient pool. Other prominent players in the global gout therapeutics market include Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Iroko Pharmaceuticals, LLC, and MERCK & CO., Inc.

Global Gout Therapeutics Market: Overview

This report studies the current as well as future prospects of the global gout therapeutics market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of gout therapeutics and new players planning to enter the market.

The report comprises an elaborate executive summary, along with a market snapshot, providing overall information on various segments considered in the scope of the study. The section also provides information and data analysis of the global gout therapeutics market in terms of drug type, distribution channel, and region.

Global Gout Therapeutics Market: Key Segments

The global gout therapeutics market has been segmented based on drug type, distribution channel, and region. In terms of drug type, the global market has been classified into colchicine, antihyperuricemic agents (urate-lowering drugs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic response modifiers (Biologics).  

Based on distribution channel, the global gout therapeutics market has been divided into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment is expected to dominate the global gout therapeutics market during the forecast period.

Research Approach

The bottom-up approach has been employed to determine the size of the global gout therapeutics market, using various market indicators obtained from secondary sources, which included analysis of launched products and mapping of demand for gout therapeutics of top market players in specific regions.

The top-down approach has been used to derive the market size of different product segments, wherein market size of parent market was obtained through secondary sources and analyzed for sales by narrowing down to revenue percentage for product segment through extensive analysis of investor presentations, press releases, primary interviews, and others.

Data triangulation is based on both secondary research (top-down and bottom-up approaches) and primary research. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. Market value and forecast, in terms of US$ Mn, for each segment has been provided for the period from 2017 to 2027.

The report also provides compound annual growth rate (CAGR %) for each segment for the forecast period from 2019 to 2027, considering 2018 as the base year.

The overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have significant impact on the global gout therapeutics market and could influence it in the near future.

Market attractiveness analysis has been provided to explain the intensity of competition in the market across regions. These analyses are likely to help market players take strategic decisions to strengthen their positions and grow their share in the global gout therapeutics market. The report also comprises pipeline analysis and epidemiological overview of gout.

Global Gout Therapeutics Market: Regional Outlook

In terms of region, the global gout therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Market size and forecast for each of these regions have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year.

The report also provides market size and forecast for major countries in the above mentioned regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and growth opportunities has been provided in the overview section.

Companies Mentioned in the Report

Some of the major players operating in the global gout therapeutics market are

  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited.
    Novartis AG, Mylan N.V.
  • Horizon Pharma plc
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • Iroko Pharmaceuticals, LLC
  • MERCK & CO., Inc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

The global gout therapeutics market has been segmented as follows:

Drug Type

  • Colchicine
  • Antihyperuricemic Agents (Urate-Lowering Drugs)
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Biologic Response Modifiers (Biologics)

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1.Preface
      1.1. Market Definition and Scope
      1.2. Market Segmentation
      1.3. Key Research Objectives
      1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Gout Therapeutics Market 

4. Market Overview
      4.1. Introduction
              4.1.1. Component Definition
              4.1.2. Industry Evolution / Developments
      4.2.  Overview
      4.3. Market Dynamics
              4.3.1. Drivers
              4.3.2. Restraints
              4.3.3. Opportunities
      4.4. Global Gout Therapeutics Market Analysis and Forecast, 2017–2027
              4.4.1. Market Revenue Projections (US$ Mn)
      4.5. Porter’s Five Force Analysis

5. Market Outlook
      5.1.Epidemiological Overview of Gout Arthritis
      5.2.Pipeline Analysis

6. Global Gout Therapeutics Market Analysis and Forecast, by Component 
      6.1. Introduction & Definition
      6.2. Key Findings / Developments
      6.3. Global Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
              6.3.1. Colchicine
              6.3.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              6.3.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              6.3.4. Corticosteroids
              6.3.5. Biologic Response Modifiers (Biologics)
      6.4. Global Gout Therapeutics Market Attractiveness, by Drug Type  

7 Global Gout Therapeutics Market Analysis and Forecast, by Distribution Channel 
      7.1. Introduction & Definition
      7.2. Key Findings / Developments
      7.3. Global Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
              7.3.1. Hospital Pharmacy
              7.3.2. Retail Pharmacy
              7.3.3. Online Pharmacy
      7.4. Global Gout Therapeutics Market Attractiveness, by Distribution Channel 

8. Global Gout Therapeutics Market Analysis and Forecast, by Region
      8.1. Key Findings
      8.2. Global Gout Therapeutics Market Value Forecast, by Region
              8.2.1. North America 
              8.2.2. Europe 
              8.2.3. Asia Pacific 
              8.2.4. Latin America 
              8.2.5. Middle East & Africa 
      8.3. Global Gout Therapeutics Market Attractiveness, by Country/Region

9. North America Gout Therapeutics Market Analysis and Forecast
      9.1. Introduction
              9.1.1. Key Findings
      9.2. North America Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
              9.2.1. Colchicine
              9.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              9.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              9.2.4. Corticosteroids
              9.2.5. Biologic Response Modifiers (Biologics)
      9.3. North America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
              9.3.1. Hospital Pharmacy
              9.3.2. Retail Pharmacy
              9.3.3. Online Pharmacy
      9.4. North America Gout Therapeutics Market Value Forecast, by Country, 2017–2027
              9.4.1. U.S.
              9.4.2. Canada
      9.5. North America Gout Therapeutics Market Attractiveness Analysis 
              9.5.1. By Drug Type
              9.5.2. By Distribution Channel 
              9.5.3. By Country

10. Europe Gout Therapeutics Market Analysis and Forecast
      10.1. Introduction
              10.1.1. Key Findings
      10.2. Europe Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
              10.2.1. Colchicine
              10.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              10.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              10.2.4. Corticosteroids
              10.2.5. Biologic Response Modifiers (Biologics)
      10.3. Europe Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
              10.3.1. Hospital Pharmacy
              10.3.2. Retail Pharmacy
              10.3.3. Online Pharmacy
      10.4. Europe Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
              10.4.1. Germany
              10.4.2. U.K.
              10.4.3. France
              10.4.4. Spain
              10.4.5. Italy
              10.4.6. Rest of Europe
      10.5. Europe Gout Therapeutics Market Attractiveness Analysis 
              10.5.1. By Drug Type 
              10.5.2. By Distribution Channel 
              10.5.3. By Country/Sub-region

11. Asia Pacific Gout Therapeutics Market Analysis and Forecast
      11.1.Introduction
              11.1.1. Key Findings
      11.2. Asia Pacific Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
              11.2.1. Colchicine
              11.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              11.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              11.2.4. Corticosteroids
              11.2.5. Biologic Response Modifiers (Biologics)
      11.3. Asia Pacific Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
              11.3.1. Hospital Pharmacy
              11.3.2. Retail Pharmacy
              11.3.3. Online Pharmacy
      11.4. Asia Pacific Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
              11.4.1. China
              11.4.2. Japan
              11.4.3. India
              11.4.4. Australia & New Zealand
              11.4.5. Rest of Asia Pacific
      11.5. Asia Pacific Gout Therapeutics Market Attractiveness Analysis 
              11.5.1. By Drug Type 
              11.5.2. By Distribution Channel 
              11.5.3. By Country/Sub-region

12. Latin America Gout Therapeutics Market Analysis and Forecast
      12.1.Introduction
              12.1.1. Key Findings
      12.2. Latin America Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
              12.2.1. Colchicine
              12.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              12.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              12.2.4. Corticosteroids
              12.2.5. Biologic Response Modifiers (Biologics)
      12.3. Latin America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
              12.3.1. Hospital Pharmacy
              12.3.2. Retail Pharmacy
              12.3.3. Online Pharmacy
      12.4. Latin America Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
              12.4.1. Brazil
              12.4.2. Mexico
              12.4.3. Rest of Latin America
      12.5. Latin America Gout Therapeutics Market Attractiveness Analysis 
              12.5.1. By Drug Type
              12.5.2. By Distribution Channel 
              12.5.3. By Country/Sub-region

13. Middle East & Africa Gout Therapeutics Market Analysis and Forecast
      13.1.Introduction
              13.1.1. Key Findings
      13.2. Middle East & Africa Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2027
              13.2.1. Colchicine
              13.2.2. Antihyperuricemic agents (Urate-Lowering Drugs) 
              13.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
              13.2.4. Corticosteroids
              13.2.5. Biologic Response Modifiers (Biologics)
      13.3. Middle East & Africa Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2027
              13.3.1. Hospital Pharmacy
              13.3.2. Retail Pharmacy
              13.3.3. Online Pharmacy
      13.4. Middle East & Africa Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2027
              13.4.1. GCC Countries
              13.4.2. South Africa
              13.4.3. Rest of Middle East & Africa
      13.5.Market Attractiveness Analysis 
              13.5.1. By Drug Type
              13.5.2. By Distribution Channel 
              13.5.3. By Country/Sub-region

14. Competition Landscape
      14.1. Company Profiles
              14.1.1. Takeda Pharmaceutical Company Limited
                         14.1.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.1.2 Product Portfolio
                         14.1.1.3. SWOT Analysis 
                         14.1.1.4. Strategic Overview
                         14.1.1.5. Financial Overview
              14.1.2. Teijin Pharma Limited
                         14.1.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.2.2 Product Portfolio
                         14.1.2.3. SWOT Analysis 
                         14.1.2.4. Strategic Overview
              14.1.3. Novartis AG
                         14.1.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.3.2 Product Portfolio
                         14.1.3.3. SWOT Analysis 
                         14.1.3.4. Strategic Overview
                         14.1.3.5. Financial Overview
              14.1.4. Mylan N.V.
                         14.1.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.4.2 Product Portfolio
                         14.1.4.3. SWOT Analysis 
                         14.1.4.4. Strategic Overview
                         14.1.4.5. Financial Overview
              14.1.5. Horizon Pharma plc.
                         14.1.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.5.2 Product Portfolio
                         14.1.5.3. SWOT Analysis 
                         14.1.5.4. Strategic Overview
                         14.1.5.5. Financial Overview
              14.1.6. Teva Pharmaceutical Industries Ltd.
                         14.1.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.6.2 Product Portfolio
                         14.1.6.3. SWOT Analysis 
                         14.1.6.4. Strategic Overview
                         14.1.6.5. Financial Overview
              14.1.7 Hikma Pharmaceuticals PLC
                         14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.7.2 Product Portfolio
                         14.1.7.3. SWOT Analysis 
                         14.1.7.4. Strategic Overview
                         14.1.7.5. Financial Overview
              14.1.8. Iroko Pharmaceuticals, LLC 
                         14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.7.2 Product Portfolio
                         14.1.7.3. SWOT Analysis 
                         14.1.7.4. Strategic Overview
              14.1.9. MERCK & CO., Inc.
                         14.1.9.1. Company Overview (HQ, Business Segments, Employee Strengths)
                         14.1.9.2 Product Portfolio
                         14.1.9.3. SWOT Analysis         
                         14.1.9.4. Strategic Overview
                         14.1.9.5. Financial Overview

List of Tables

Table 01: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 2: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 3: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 4: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 5: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 6: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 
2017–2027
Table 7: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 8: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 9: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 10: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 11: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 12: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 13: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 14: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 15: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 16: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 17: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027
Table 18: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Figures

Figure 1: Global Gout Therapeutics Market Value (US$ Mn), by Drug Type 2018 (A).
Figure 2: Global Gout Therapeutics Market Share (%), by Distribution Channel, 2017 (A).
Figure 3: Opportunity Map, Drug type.
Figure 4: Opportunity Map, Distribution Channel.
Figure 5: Key Industry Developments.
Figure 6: Global Gout Therapeutics Market Value (US$ Mn) Forecast, 2017–2027
Figure 7: Global Gout Therapeutics Market Value Share, by Drug Type (2018)
Figure 8: Global Gout Therapeutics Market Value Share, by Distribution channel (2018)
Figure 9: Global Gout Therapeutics Market Value Share, by Region (2018)
Figure 10: Global Gout Therapeutics Market Value Split, by Type (2018)
Figure 11: Global Gout Therapeutics Market Value Split, by Region (2018).
Figure 12: Global Gout Therapeutics Market Value Split, by Distribution Channel (2018)
Figure 13: Global Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 14: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Antihyperuricemic Agents (Urate-Lowering Drugs), 2017–2027
Figure 15: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Non-steroidal Anti-inflammatory Drugs (NSAIDs), 2017–2027
Figure 16: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2017–2027
Figure 17: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Biologics, 2017–2027
Figure 18: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Colchicine, 2017–2027
Figure 19: Global Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 20: Global Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 21: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2017–2027
Figure 22: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2017–2027
Figure 23: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2017-2027
Figure 24: Global Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 25: Global Gout Therapeutics Market Value Share Analysis, by Region, 2018 and 2027
Figure 26: Global Gout Therapeutics Market Attractiveness Analysis, by Region, 2019?2027
Figure 27: North America Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 28: North America Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 29: North America Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 30: North America Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 31: North America Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 32: North America Gout Therapeutics Market Attractiveness Analysis, by Country, 2019–2027
Figure 33: Europe Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 34: Europe Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 35: Europe Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 36: Europe Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 37: Europe Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 38: Europe Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 39: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 40: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 41: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 42: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 43: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 44: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 45: Latin America Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 46: Latin America Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 47: Latin America Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 48: Latin America Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 49: Latin America Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 50: Latin America Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 51: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 52: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018 and 2027
Figure 53: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 54: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019–2027
Figure 55: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 56: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 57: Takeda Breakdown of Net Sales, by Region.
Figure 58: Takeda Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2018
Figure 59: Takeda R&D Expenses (US$ Bn), 2016–2018
Figure 60: Novartis AG Breakdown of Net Sales, by Region, 2018
Figure 61: Novartis AG Breakdown of Net Sales, by Business Segment, 2018.
Figure 62: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018.
Figure 63: Novartis AG R&D Expenses (US$ Mn), 2016–2018.
Figure 64: Teva Pharmaceutical Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2018.
Figure 65: Teva Pharmaceutical R&D Expenses (US$ Bn), 2016–2018.
Figure 66: Teva Pharmaceutical Breakdown of Net Sales, By Region 2018.
Figure 67: Teva Pharmaceutical Breakdown of Net Sales, (Overall Company Level), 2018.
Figure 68: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
Figure 69: Mylan N.V. R&D Expenses (US$ Mn), 2016–2018
Figure 70: Mylan N.V.  Breakdown of Net Sales (%), by Region, 2018.
Figure 71: Breakdown of Net Sales (%), by Business Segment, 2018.
Figure 72: Horizon Pharma plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018.
Figure 73: Horizon Pharma plc R&D Expenses (US$ Mn), 2016–2018.
Figure 74: Horizon Pharma plc Breakdown of Net Sales, by Business Segment, 2018.
Figure 75: Horizon Pharma plc Breakdown of Net Sales, by Region, 2018.
Figure 76: Hikma Pharmaceuticals PLC Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
Figure 77: Hikma Pharmaceuticals PLC R&D Expenses (US$ Mn), 2016–2018.
Figure 78: Hikma Pharmaceuticals PLC Breakdown of Net Sales, by Business Segment, 2018
Figure 79: Hikma Pharmaceuticals PLC Breakdown of Net Sales, by Region, 2018.
Figure 80: MERCK & CO., Inc Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018
Figure 81: MERCK & CO., Inc PLC R&D Expenses (US$ Mn), 2016–2018.
Figure 82 MERCK & CO., Inc PLC Breakdown of Net Sales, by Business Segment, 2018
Figure 83: MERCK & CO., Inc PLC Breakdown of Net Sales, by Region, 2018.

 

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Gout Therapeutic Market